首页 拜玛林制药(usBMRN)-基本信息

拜玛林制药(usBMRN)-基本信息

日报更新时间:04-17 11:30

周报更新时间:04-11 03:39

行情信息

今开价:79.12

最高价:79.6

成交量:868641.0

昨收价:78.77

最低价:78.07

最新价:79.4

行情图标
概要信息

中文名称:拜玛林制药


英文名称:Biomarin Pharmaceutical


行业:医疗


简介:Biomarin Pharmaceutical Inc.位于特拉华州,研发生产创新生物技术药物,治疗严重的疾病和健康问题


电话:1-415-5066700


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

1997年,Christopher Starr Ph.D. 和 Grant W. Denison Jr. 以从Glyko Biomedical获得的150万美金创立了BioMarin,并于1999年IPO,种子投资公司包括MPM Bioventures、Grosvenor Fund 和 Florian Schönharting。拜玛林制药公司主要从事慢性基因疾病以酵素为基材的治疗药品的研发逾开发工作,BioMarin Pharmaceutical公司已推出的药品 BM101是针对黏多糖体病症(乡MPS-1)的儿童进行治疗的产品。后续并推出BM102,进行黏多糖体(MPS-VI)的治疗。另有多种利用碳水化合物分析法,开发它种酵素治疗产品。拜玛林制药公司商用阶段药物包括: Vimizim——酶替代疗法治疗MPS IV A(一种溶酶体贮积症); Naglazyme——N-乙酰基-4-硫酸酯酶的重组形式,治疗VI型粘多糖体病症; Kuvan——6R-BH4的专有合成的口服剂型,用于治疗苯丙酮尿症患者(PKU,一种遗传代谢性疾病); Aldurazyme—— 用于治疗I型粘多糖体病症(一种遗传性疾病); Firdapse——3,4-二氨基吡啶,用于兰伯特肌无力综合征的治疗(一种自身免疫性疾病)。拜玛林制药公司临床阶段药物包括: Kyndrisa——一种exon-51 skipping化合物,用于治疗杜兴氏肌营养不良的(DMD); Pegvaliase——酶替代疗法,用于治疗PKU; Reveglucosidase阿尔法——酶替代疗法治疗庞贝氏症; Vosoritide——肽疗法,用于治疗软骨发育不全症; BMN 044、BMN 045、BMN 053——用于DMD治疗; Cerliponase阿尔法——用于婴儿神经元蜡样脂褐质的治疗; BMN 270——一种用于治疗A型血友病的AAV VIII矢量、Factor VIII基因治疗药物; 此外,BioMarin Pharmaceutical还有临床前阶段产品,如:治疗遗传和代谢性疾病的α-N-乙酰氨基葡(alpha-N-acetyglucosaminidase)。拜玛林制药公司BioMarin Pharmaceutical(BMRN)收购历史: 2002年,拜玛林制药公司收购Glyko Biomedical; 2009年,BioMarin Pharmaceutical收购Huxley Pharmaceuticals, Inc.; 2010年,拜玛林制药公司收购LEAD Therapeutics, Inc.、ZyStor Therapeutics, Inc.; 2012年,BioMarin Pharmaceutical收购Zacharon Pharmaceuticals; 2014年,拜玛林制药公司以200万美金从Repligen(NASDAQ:RGEN)收购组蛋白去乙酰化酶抑制剂化学库; 2014年11月,BioMarin Pharmaceutical以8.4亿美金收购Prosensa(原NASDAQ:RNA)。

交易日期 交易人 职位 类型 交易份额 价格
2019-07-08 Anderson (Elizabeth M) Director Buy 4490 --
2019-06-16 Lawlis (V Bryan) Director Sell 3750 81.08
2019-06-16 Lawlis (V Bryan) Director Buy 3750 21.51
2019-06-10 Meier (Richard A) Director Gift 6000 --
2019-06-04 Ajer (Jeffrey Robert) Officer Buy 14160 --
2019-06-04 Baffi (Robert A) Officer Buy 14160 --
2019-06-04 Davis (George Eric) General Counsel Gift 300 --
2019-06-03 Hombach (Robert J) Director Buy 4430 --
2019-06-03 Lawlis (V Bryan) Director Buy 4430 --
2019-06-03 Lewis (Alan J. Ph.D.) Director Buy 4430 --
2019-06-03 Meier (Richard A) Director Buy 4430 --
2019-06-03 Pyott (David E I) Director Buy 4430 --
2019-06-03 Slamon (Dennis J) Director Buy 4430 --
2019-06-03 Heron (Elaine J) Director Buy 4430 --
2019-06-03 Grey (Michael G.) Director Buy 4430 --
2019-06-03 Dere Willard H Director Buy 4430 --
2019-05-09 Bienaime (Jean-Jacques) Chief Executive Officer Buy 10000 14.39
2019-05-09 Bienaime (Jean-Jacques) Chief Executive Officer Sell 10000 82.52
2019-05-08 Bienaime (Jean-Jacques) Chief Executive Officer Sell 4000 81.97
2019-05-08 Bienaime (Jean-Jacques) Chief Executive Officer Buy 4000 14.39
2019-05-07 Bienaime (Jean-Jacques) Chief Executive Officer Buy 4000 14.39
2019-05-07 Bienaime (Jean-Jacques) Chief Executive Officer Sell 4000 82.16
2019-04-29 Bienaime (Jean-Jacques) Chief Executive Officer Buy 309 68.78
2019-04-29 Ajer (Jeffrey Robert) Officer Buy 309 68.78
2019-04-29 Spiegelman (Daniel Keith) Chief Financial Officer Buy 176 68.78

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
T. Rowe Price Associates, Inc. 2481541 1.39% 207251 9.11% 2019-03-31
Sands Capital Management, LLC 5881446 3.28% -226014 -3.70% 2019-03-31
Baker Bros Advisors LP 7589294 4.24% -- -- 2019-03-31
Jennison Associates LLC 12412593 6.93% 812133 7.00% 2019-03-31
BlackRock Inc 12663369 7.07% -915193 -6.74% 2019-03-31
PRIMECAP Management Company 14190873 7.92% 5700 0.04% 2019-03-31
Vanguard Group Inc 15709874 8.77% 167970 1.08% 2019-03-31
Capital Research Global Investors 17749061 9.91% -555102 -3.03% 2019-03-31
Capital Research and Management Company 23917470 13.33% 2837884 13.46% 2019-07-31
Viking Global Investors LP 5128909 2.86% 37272 0.73% 2019-03-31
ClearBridge Advisors, LLC 5005318 2.80% 499656 11.09% 2019-03-31
Vanguard Investments Australia Ltd 4981111 2.78% 11444 0.23% 2019-07-31
Waddell & Reed Investment Management Co 2523973 1.41% -336902 -11.78% 2019-03-31
Waddell & Reed Financial Inc 2523973 1.41% -336902 -11.78% 2019-03-31
Legg Mason Partners Fund Advisor, LLC 2534310 1.41% 444733 21.28% 2019-07-31
Palo Alto Investors, LLC 2641485 1.48% 81752 3.19% 2019-03-31
Ameriprise Financial Inc 2653174 1.48% -8046 -0.30% 2019-03-31
Harbor Capital Advisors Inc 2893136 1.61% -883415 -23.39% 2019-07-31
BlackRock Fund Advisors 4241109 2.36% 14769 0.35% 2019-07-31
State Street Corporation 4636152 2.59% 738589 18.95% 2019-03-31
Amvescap Plc. 3315049 1.85% 17892 0.54% 2018-12-31
PGIM Investments LLC 2887350 1.61% -325195 -10.12% 2019-06-30
Geode Capital Management, LLC 3287014 1.84% 1736026 111.93% 2018-12-31
Capital Research & Mgmt Co - Division 3 3412644 1.91% 1308641 62.20% 2018-12-31
TIAA-CREF Investment Management LLC 2638888 1.48% 1574735 147.98% 2018-09-30
Goldman Sachs Group Inc 2742244 1.54% -484416 -15.01% 2018-06-30
Fidelity Management & Research Company 3701360 2.08% -714159 -16.17% 2018-11-30
BlackRock Institutional Trust Company NA 4565488 2.56% -121511 -2.59% 2018-06-30
Temasek Holdings Ltd. 3472712 1.95% -- -- 2018-06-30
State Street Corp 3803137 2.14% -220199 -5.47% 2018-06-30
Fidelity Management and Research Company 2051024 1.16% -1894587 -48.02% 2018-06-30
Goldman, Sachs & Co. 1997247 1.13% -337219 -14.45% 2018-06-30
Citadel Advisors Llc 1833405 1.03% 457896 33.29% 2018-06-30
Capital World Investors 1833103 1.03% 158184 9.44% 2018-06-30
Invesco Advisers, Inc 1673112 0.94% -908767 -35.20% 2018-06-30
venBio Select Advisor LLC 1622770 0.91% -88225 -5.16% 2018-06-30
Prudential Investment Management Inc 11968395 6.81% 2571492 27.37% 2017-12-31
Franklin Advisers Inc 1470212 0.84% 83868 6.05% 2017-12-31
Balyasny Asset Management LLC 1751391 1.00% 689779 64.97% 2017-12-31
Manning & Napier Advisors, LLC 2065710 1.18% -52776 -2.49% 2017-09-30
Invesco PowerShares Capital Mgmt LLC 1374642 0.78% -109332 -7.37% 2017-06-30
OppenheimerFunds Inc 1348373 0.77% -239577 -15.09% 2017-09-30
J.P. Morgan Investment Management Inc 2945421 1.72% 362380 14.03% 2016-09-30
Wells Capital Management Inc. 1888612 1.10% -243530 -11.42% 2016-09-30
Fred Alger Management Inc 1644829 0.96% 209042 14.56% 2016-09-30
Columbia Mangmt Investment Advisers, LLC 1479114 0.86% 20003 1.37% 2016-09-30
The Vanguard Group 8848001 3.00% 1107504285 0.10% 1999-11-30
BlackRock, Inc. 9237747 3.00% 1156288792 0.10% 1999-11-30
FMR LLC 13431666 3.00% 1681241633 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
T. Rowe Price Health Sciences Fund 1141988 0.64% -176000 -13.35% 2019-06-30
Vanguard Extended Market Index Fund 2457210 1.37% -8497 -0.34% 2019-06-30
Harbor Capital Appreciation Fund 2893136 1.61% -883415 -23.39% 2019-06-30
Vanguard PrimeCap Fund 4138741 2.31% -- -- 2019-03-31
Vanguard Mid-Cap Index Fund 4362161 2.43% 84313 1.97% 2019-06-30
Vanguard Total Stock Market Index Fund 4909180 2.74% 6869 0.14% 2019-06-30
Vanguard Capital Opportunity Fund 5087160 2.83% -10000 -0.20% 2019-03-31
American Funds AMCAP Fund 8939900 4.98% -- -- 2019-06-30
American Funds Growth Fund of Amer 9647315 5.38% 2405800 33.22% 2019-06-30
ClearBridge Large Cap Growth Fund 1857322 1.03% 389011 26.49% 2019-06-30
iShares Nasdaq Biotechnology ETF 1767716 0.99% 18395 1.05% 2019-07-30
PrimeCap Odyssey Growth Fund 1735296 0.97% -- -- 2019-06-30
Vanguard Morgan 1160222 0.65% -137242 -10.58% 2019-03-31
First Trust NYSE Arca Biotech Fund 1165702 0.65% -2809 -0.24% 2019-07-31
CREF Growth Account 1194128 0.67% 243900 25.67% 2019-06-30
Vanguard Growth Index Fund 1279574 0.71% 49762 4.05% 2019-06-30
American Funds New World Fund 1357279 0.76% -- -- 2019-06-30
American Funds American Balanced Fund 1451000 0.81% 141000 10.76% 2019-06-30
PrimeCap Odyssey Aggressive Growth Fund 1482165 0.83% 4000 0.27% 2019-06-30
Invesco QQQ Trust 1608320 0.90% 1421 0.09% 2019-07-31
Vanguard Mid-Cap Growth Index Fund 1140148 0.64% 51264 4.71% 2019-06-30
PGIM Jennison Health Sciences Fund 1103318 0.62% -- -- 2019-05-31
Ivy Science and Technology Fund 1021600 0.57% -49600 -4.63% 2018-12-31
VA CollegeAmerica AMCAP Fd 10177000 5.71% -168500 -1.63% 2018-12-31
VA CollegeAmerica The Gr Fd of Amer 8145515 4.57% -420000 -4.90% 2018-12-31
VA CollegeAmerica New Wld Fd 1595179 0.89% 104000 6.97% 2018-12-31
AZ InvestEd Ivy Science & Tech Fund 1021600 0.57% -49600 -4.63% 2018-12-31
VA CollegeAmerica The New Economy Fd 1543730 0.87% 8600 0.56% 2018-09-30
American Funds New Economy Fund 1543730 0.87% 8600 0.56% 2018-09-30
Fidelity 1100371 0.62% -90000 -7.56% 2018-09-30
PRIMECAP Odyssey Growth 1726296 0.97% 41980 2.49% 2018-06-30
AZ InvestEd Ivy Science & Tech E 1071200 0.60% -- -- 2018-06-30
Vanguard Mid-Cap Growth ETF 1073173 0.60% 4664 0.44% 2018-07-31
VA CollegeAmerica New World 529F 1242179 0.70% 75000 6.43% 2018-06-30
VA CollegeAmerica Amcap 529F 10345500 5.83% -- -- 2018-06-30
Vanguard Capital Opportunity Inv 5092160 2.87% 31480 0.62% 2018-06-30
Vanguard Total Stock Mkt Idx 4439861 2.50% 19892 0.45% 2018-07-31
Vanguard Mid Cap Index I 4184831 2.36% 23786 0.57% 2018-07-31
Vanguard PRIMECAP Inv 4111290 2.32% 305190 8.02% 2018-06-30
Harbor Capital Appreciation Instl 3335218 1.88% -27388 -0.81% 2018-06-30
Vanguard Extended Market Idx Inv 2343885 1.32% 40505 1.76% 2018-07-31
iShares Nasdaq Biotechnology 2004917 1.11% -3816 -0.19% 2018-09-12
VA CollegeAmerica Grth Fund of Amer 529F 8201515 4.62% 68000 0.84% 2018-06-30
Vanguard Growth Index Inv 1243864 0.70% -3480 -0.28% 2018-07-31
T. Rowe Price Health Sciences 1466067 0.83% 235220 19.11% 2018-06-30
PRIMECAP Odyssey Aggressive Growth 1486865 0.84% 22860 1.56% 2018-06-30
Prudential Jennison Health Sciences A 1416506 0.80% -- -- 2018-07-31
PowerShares QQQ ETF 1447805 0.81% -5580 -0.38% 2018-09-13
VA CollegeAmerica New Economy 529F 1535130 0.86% -- -- 2018-06-30
Invesco American Franchise A 986142 0.56% 83490 9.25% 2017-12-31
CREF Growth R1 965839 0.55% -8605 -0.88% 2017-12-31
Vanguard Mid Cap Growth Inv 916202 0.53% 530740 137.69% 2016-09-30
T. Rowe Price Growth Stock 917359 0.53% -3200 -0.35% 2016-09-30
Prudential Jennison Mid Cap Growth A 857583 0.50% -26675 -3.02% 2016-12-31
Touchstone Sands Capital Select Growth Z 968681 0.60% -53000 -5.20% 2016-09-30
VA CollegeAmerica AMCAP 6848011 4.20% -77503 -1.10% 2015-09-30
Fidelity® Select Biotechnology Portfolio 5122477 3.20% 69860 1.40% 2015-09-30
VA CollegeAmerica New Economy 2172400 1.40% 86000 4.10% 2015-09-30
T. Rowe Price Growth Stock Fund 2025100 1.30% -222800 -9.90% 2015-09-30
Prudential Jennison Health Sciences 1752708 1.10% -- -- 2015-09-30
Touchstone Sands Capital Select Growth 1651000 1.00% -19000 -1.10% 2015-08-31
Fidelity Advisor® Biotechnology Fund 1417848 0.90% 17097 1.20% 2015-09-30
VA CollegeAmerica Growth Fund of America 8060428 5.00% 45000 0.60% 2015-09-30
JPMorgan Large Cap Growth 1381900 0.90% 7300 0.50% 2015-09-30

David E. I. Pyott David E. I. Pyott is a British businessperson who has been at the head of 7 different companies. Currently, he holds the position of Chairman of Bioniz Therapeutics, Inc., Chief Executive Officer & Director at Serica Technologies, Inc. and President of Vicept Therapeutics, Inc. He is also President at International Council of Ophthalmology Foundation and on the board of 13 other companies. He previously occupied the position of Head-Nutrition Division at Novartis AG and President & Chief Executive Officer of Sandoz Nutrition Corp. (a subsidiary of Novartis AG), Chairman at California Healthcare Institute and Chairman & Chief Executive Officer of Allergan, Inc. Dr. Pyott received a graduate degree from The University of Edinburgh and an MBA from London Business School.
George Eric Davis Currently, George Eric Davis holds the position of Secretary, Executive VP & General Counsel at BioMarin Pharmaceutical, Inc. and Secretary & Director at Biomarin (U.K.) Ltd. (a subsidiary of BioMarin Pharmaceutical, Inc.). In the past he occupied the position of Principal at Paul, Hastings, Janofsky & Walker LLP. Mr. Davis received an undergraduate degree from the University of California, Berkeley and a graduate degree from The University of San Francisco School of Law.
Wayne T. Pan Wayne T. Pan is on the board of Semler Scientific, Inc. and Associate Medical Director at San Francisco Health Authority and Medical Director-Medical Sciences at BioMarin Pharmaceutical, Inc. He previously was Chief Medical Officer of Thrasys, Inc., Chief Medical Informatics Officer at Health Access Solutions, Inc., Chief Medical Officer at Affinity Medical Solutions LLC, Medical Director of Clover Health Labs LLC, Chief Medical Officer of Santa Clara County Individual Practice Association, Chief Medical Officer at Applied Research Works, Inc., Chief Medical Officer for Pacific Partners Management Services, Inc., Medical Director-Quality Care & Health Economics at Genentech, Inc. and Chief Medical Officer for Alameda Alliance for Health. Dr. Pan received an undergraduate degree from The Johns Hopkins University, a doctorate from Icah School of Medicine at Mount Sinai and an MBA from The Wharton School of the University of Pennsylvania.
Dennis Joseph Slamon Dennis Joseph Slamon is on the board of BioMarin Pharmaceutical, Inc. and Translational Research In Oncology and Director-Clinical & Translational Research at Jonsson Comprehensive Cancer Center, Director-Revlon & UCLA Women Cancer Research at David Geffen School of Medicine and Executive Vice Chairman-Research at the University of California, Los Angeles. Dr. Slamon received an undergraduate degree from Washington & Jefferson College and a doctorate from Pritzker School of Medicine.
Jean-Jacques Bienaim�0�1�0�8 Jean-Jacques Bienaim�0�1�0�8 holds the position of Chairman & Chief Executive Officer of BioMarin Pharmaceutical, Inc. He is also on the board of Incyte Corp., Biotechnology Innovation Organization and Pharmaceutical Research & Manufacturers of America. In the past he occupied the position of Lead Independent Director at NeurogesX, Inc., President & Chief Executive Officer at SangStat Medical Corp., Chairman, President & Chief Executive Officer at Genencor International, Inc., Director-Cardiopulmonary Products Marketing at Genentech, Inc. and Vice President & General Manager at Rhone-Poulenc Rorer Pharmaceuticals, Inc. Jean-Jacques Bienaim�0�1�0�8 received an undergraduate degree from ESCP Europe Campus Paris, an MBA from The Wharton School of the University of Pennsylvania and an undergraduate degree from The University of Texas.
Richard A. Meier Richard A. Meier is on the board of BioMarin Pharmaceutical, Inc. In his past career he was CFO, Executive VP & President-International at Owens & Minor, Inc., Chief Financial Officer & Executive Vice President of Teleflex, Inc., President & Chief Operating Officer of Advanced Medical Optics, Inc., Chief Financial Officer & Executive Vice President of Valeant Pharmaceuticals International Corp., Senior Vice President of Schroder & Co., Inc., Principal at Manufacturers Hanover Corp., Principal at Greyhound Lines, Inc., Principal at Australian Capital Equity Pty Ltd. and Principal at Salomon Smith Barney, Inc. He received an undergraduate degree from Princeton University.
Richard J. Ranieri Richard J. Ranieri holds the position of Senior VP-Human Resources & Corporate Affairs at BioMarin Pharmaceutical, Inc. Mr. Ranieri is also on the board of Xencor, Inc. In the past he occupied the position of Chief Administrative Officer & SVP-Human Resources at Neurocrine Biosciences, Inc., Executive VP-Human Resources & Administration at Sunovion Pharmaceuticals, Inc., Principal at GlaxoSmithKline LLC, Executive Vice President-Human Resources for Dendreon Corp. and Senior Vice President-Human Resources at Genencor International, Inc. Richard J. Ranieri received an undergraduate degree from Villanova University and a graduate degree from Rider University.
Daniel K. Spiegelman Daniel K. Spiegelman founded Rapidscan Pharma Solutions, Inc. He is Chief Financial Officer & Executive Vice President for BioMarin Pharmaceutical, Inc. Mr. Spiegelman is also on the board of Rapidscan Pharma Solutions, Inc. and Tizona Therapeutics, Inc. In his past career he held the position of Chief Executive Officer for Filtini, Inc., Chairman of Relypsa, Inc., Chief Financial Officer & Senior Vice President at CV Therapeutics, Inc. and Treasurer at Genentech, Inc. He received an undergraduate degree from Stanford University and an MBA from Stanford Graduate School of Business.
Alan J. Lewis Dr. Alan J. Lewis is an Independent Director at Assembly Biosciences, Inc., a President, Chief Executive Officer & Director at DiaVacs, Inc., a Chairman at Batu Biologics, Inc., a Chairman at Cellastra, Inc., an Independent Non-Executive Director at BioMarin Pharmaceutical, Inc., a Chairman at Cytochroma, Inc. and a Chairman at NeuraMetrix, Inc. He is on the Board of Directors at Scancell Holdings Plc, Assembly Biosciences, Inc., DiaVacs, Inc., Targazyme, Inc., BioMarin Pharmaceutical, Inc., BIOCOM, Capella Therapeutics, Inc., Habit DX, Inc., Rincon Pharmaceuticals, Inc., Scancell Ltd. and Sosei Co. Ltd. Dr. Lewis was previously employed as a Chief Executive Officer & Director by Medistem, Inc., a President, Chief Executive Officer & Director by Ambit Biosciences Corp., a President & Chief Executive Officer by Juvenile Diabetes Research Foundation Ltd., a President & Chief Executive Officer by Novocell, Inc. (Old), a President & Chief Executive Officer by Novocell, Inc. (New), a President by Celgene Research & Development Co. LLC, a President & Chief Executive Officer by Signal Pharmaceuticals, Inc., a Vice President-Research by Wyeth-Ayerst Research, a Research Associate by Yale University, a Non-Executive Director by Biotica Technology Ltd., a Chairman by LymphoSign, Inc., a Chairman by Novation Pharmaceuticals, Inc., a Chief Executive Officer by Signal Therapeutics, Inc., a Non-Executive Director by Sosei Group Corp., and a Principal by Wyeth Laboratories, Inc. He also served on the board at Discovery Partners International, Inc. He received his undergraduate degree from The University of Southampton and a doctorate degree from The University of Wales.
Henry J. Fuchs Henry J. Fuchs holds the position of President-Worldwide Research & Development at BioMarin Pharmaceutical, Inc. He is also on the board of Genomic Health, Inc. and Mirati Therapeutics, Inc. In the past Dr. Fuchs occupied the position of Independent Director at Ardea Biosciences, Inc., Chief Medical Officer & Executive Vice President at Onyx Pharmaceuticals, Inc. and Principal at Genentech, Inc. Henry J. Fuchs received a doctorate from George Washington University and an undergraduate degree from Harvard University.
Robert A. Baffi Robert A. Baffi is on the board of National Institute for Bioprocessing Research & Training and Executive Vice President-Technical Operations at BioMarin Pharmaceutical, Inc. In the past Dr. Baffi held the position of Research Scientist at Cooper Biomedical, Inc. Dr. Baffi received an undergraduate degree, a doctorate and a graduate degree from City University of New York and an MBA from Regis University.
Eduardo E. Von Pervieux Eduardo E. Von Pervieux occupies the position of Chief Information Officer at BioMarin Pharmaceutical, Inc. In his past career he held the position of Director-Business Process & Technology at Pfizer Inc. and Executive Director-Systems & Business Process at Amgen, Inc. He received a graduate degree and an MBA from the University of Miami and an undergraduate degree from Florida International University.
Elaine J. Heron Elaine J. Heron is on the board of BioMarin Pharmaceutical, Inc. and 4 other companies. In the past she was Chairmen & Chief Executive Officer at Labcyte, Inc., General Manager, Vice President-Sales & Marketing at Applera Corp., Vice President-Marketing at Affymetrix, Inc., Director-Marketing at Molecular Dynamics, Inc. and Vice President of Applied Biosystems, Inc. Dr. Heron received an MBA from Pepperdine University and a doctorate and an undergraduate degree from Purdue University.
V. Bryan Lawlis Founder of Itero Biopharmaceuticals LLC, Covance Biotechnology Services, Inc. and Itero Biopharmaceuticals, Inc., V. Bryan Lawlis is on the board of Geron Corp. and 6 other companies. In his past career Dr. Lawlis occupied the position of Director at Aradigm Corp., President & Chief Executive Officer of Itero Biopharmaceuticals LLC, President & Chief Executive Officer at Itero Biopharmaceuticals, Inc., Chairman for Covance Biotechnology Services, Inc., Vice President-Process Sciences at Genentech, Inc. and Senior Scientist at Genencor International, Inc. V. Bryan Lawlis received an undergraduate degree from The University of Texas and a doctorate from Washington State University.
Geoffrey M. Nichol Presently, Geoffrey M. Nichol is Chief Medical Officer & Senior Vice President of BioMarin Pharmaceutical, Inc. He previously held the position of Executive Vice President-Research & Development at Sangamo Therapeutics, Inc., Clinical Research Physician at GlaxoSmithKline Plc, Chief Medical Officer at Ikaria, Inc., Head-Global Project Management at Novartis Pharmaceuticals Corp. and Senior Vice President-Product Development at Medarex, Inc. He received an MBA from the University of Warwick and a doctorate and an undergraduate degree from Dunedin School of Medicine.
Michael G. Grey Founder of Mirum Pharmaceuticals, Inc., Lumena Pharmaceuticals, Inc. and Reneo Pharmaceuticals, Inc., Michael G. Grey is an entrepreneur and businessperson who has been the head of 14 different companies and currently is Executive Chairman of Amplyx Pharmaceuticals, Inc., Executive Chairman for Reneo Pharmaceuticals, Inc., Executive Chairman of Spruce Biosciences, Inc., Executive Chairman for Mirum Pharmaceuticals, Inc. and Venture partner at Pappas Capital LLC. Michael G. Grey is also on the board of 7 other companies. In the past Mr. Grey held the position of President & Chief Operating Officer for Ansan, Inc., Independent Director at Ziarco Pharma Ltd., Executive Chairman for Ziarco Group Ltd., Non-Executive Chairman for IDM Pharma, Inc., President, Chief Executive Officer & Director at Lumena Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Trega Biosciences, Inc., President & Chief Executive Officer at SGX Pharmaceuticals, Inc., President & Chief Operating Officer of Ansan Pharmaceuticals, Inc., President of Biochem Therapeutic, Inc., President & Chief Executive Officer for Auspex Pharmaceuticals, Inc., Vice President-Corporate Development of Glaxo, Inc. and Vice President-Corporate Development of Glaxo Holdings Plc. He received an undergraduate degree from The University of Nottingham.
Jean-Jacques Bienaim�0�1�0�8 Jean-Jacques Bienaim�0�1�0�8 holds the position of Chairman & Chief Executive Officer of BioMarin Pharmaceutical, Inc. He is also on the board of Incyte Corp., Biotechnology Innovation Organization and Pharmaceutical Research & Manufacturers of America. In the past he occupied the position of Lead Independent Director at NeurogesX, Inc., President & Chief Executive Officer at SangStat Medical Corp., Chairman, President & Chief Executive Officer at Genencor International, Inc., Director-Cardiopulmonary Products Marketing at Genentech, Inc. and Vice President & General Manager at Rhone-Poulenc Rorer Pharmaceuticals, Inc. Jean-Jacques Bienaim�0�1�0�8 received an undergraduate degree from ESCP Europe Campus Paris, an MBA from The Wharton School of the University of Pennsylvania and an undergraduate degree from The University of Texas.
Brian R. Mueller Presently, Brian R. Mueller occupies the position of Chief Accounting Officer, SVP-Finance & Controller at BioMarin Pharmaceutical, Inc. He is also on the board of Anthera Pharmaceuticals, Inc. and Member of The American Institute of Certified Public Accountants and Vice President at Professional Control Corp. Brian R. Mueller previously was Principal at Arthur Andersen LLP and Senior Manager at KPMG LLP. He received an undergraduate degree from Northern Illinois University.
S. Michael Imperiale S. Michael Imperiale is on the board of ScripsAmerica, Inc. and Senior Director-Global Medical Affairs at BioMarin Pharmaceutical, Inc. He previously occupied the position of Director-Clinical Trials Development at Exelixis, Inc., Director-Clinical Science at InterMune, Inc., Vice President-Clinical Research Operations at Talon Therapeutics, Inc., Senior Director-Medical Sciences at Nuvelo, Inc. and Senior Associate Director-Clinical Scientific at Boehringer Ingelheim Pharmaceuticals, Inc. He received a doctorate from Hahnemann University and an undergraduate degree from Villanova University.
Robert J. Hombach Robert J. Hombach is on the board of BioMarin Pharmaceutical, Inc., CarMax, Inc., Aptinyx, Inc. and EDGe Surgical, Inc. In his past career he was Chief Financial Officer & Vice President at Baxter International, Inc., Executive VP, Chief Operations & Financial Officer at Baxalta, Inc. and President & Director at Baxter International Foundation. Mr. Hombach received an undergraduate degree from The University of Colorado and an MBA from Kellogg School of Management.
Stuart Bunting Stuart Bunting is Head-Translational Biology at BioMarin Pharmaceutical, Inc.
Jeffrey Robert Ajer Jeffrey Robert Ajer is on the board of Nektar Therapeutics and True North Therapeutics, Inc. and Chief Commercial Officer & Executive VP of BioMarin Pharmaceutical, Inc. In his past career Mr. Ajer held the position of Chief Commercial Officer & Executive VP of BioMarin Pharmaceutical, Inc., Vice President-Global Transplant Operations at Genzyme Corp., Director-Purchasing Worldwide at Valeant Pharmaceuticals International Corp. and Senior Director-Sales Operations, Bids & Contracts at SangStat Medical Corp. Mr. Ajer received an MBA and an undergraduate degree from the University of California, Irvine.
Eduardo E. Von Pervieux Eduardo E. Von Pervieux occupies the position of Chief Information Officer at BioMarin Pharmaceutical, Inc. In his past career he held the position of Director-Business Process & Technology at Pfizer Inc. and Executive Director-Systems & Business Process at Amgen, Inc. He received a graduate degree and an MBA from the University of Miami and an undergraduate degree from Florida International University.
Philip Lo Scalzo Philip Lo Scalzo is Chief Compliance Officer & Senior Vice President at BioMarin Pharmaceutical, Inc. In his past career he occupied the position of Associate Attorney at Sedgwick LLP and Assistant General Counsel at Sanofi-Aventis U.S. LLC. He received a graduate degree from Brooklyn Law School and an undergraduate degree from Boston College.
Traci McCarty Presently, Traci McCarty is Investor Relations Contact at BioMarin Pharmaceutical, Inc. In her past career she was Senior Director-Investor Relations at Onyx Pharmaceuticals, Inc.
Dennis Joseph Slamon Dennis Joseph Slamon is on the board of BioMarin Pharmaceutical, Inc. and Translational Research In Oncology and Director-Clinical & Translational Research at Jonsson Comprehensive Cancer Center, Director-Revlon & UCLA Women Cancer Research at David Geffen School of Medicine and Executive Vice Chairman-Research at the University of California, Los Angeles. Dr. Slamon received an undergraduate degree from Washington & Jefferson College and a doctorate from Pritzker School of Medicine.
Willard H. Dere Willard H. Dere is on the board of BioMarin Pharmaceutical, Inc., Radius Health, Inc., Mersana Therapeutics, Inc. and Seres Therapeutics, Inc. and Professor & Executive Director-Personalized Health at The University of Utah Health Sciences Center. In the past Dr. Dere was International Chief Medical Officer at Amgen, Inc. and Vice President-Endocrine & Bone at Eli Lilly & Co. He received an undergraduate degree and a doctorate from the University of California, Davis.
Dennis Joseph Slamon Dennis Joseph Slamon is on the board of BioMarin Pharmaceutical, Inc. and Translational Research In Oncology and Director-Clinical & Translational Research at Jonsson Comprehensive Cancer Center, Director-Revlon & UCLA Women Cancer Research at David Geffen School of Medicine and Executive Vice Chairman-Research at the University of California, Los Angeles. Dr. Slamon received an undergraduate degree from Washington & Jefferson College and a doctorate from Pritzker School of Medicine.
Elizabeth McKee Anderson Ms. Elizabeth M. Anderson is an Independent Non-Executive Director at Huntsworth Plc, an Independent Director at Bavarian Nordic A/S and an Independent Director at Bavarian Nordic GmbH. She is on the Board of Directors at BioMarin Pharmaceutical, Inc., Insmed, Inc., Aro Biotherapeutics Co., Huntsworth Plc, Bavarian Nordic A/S, Bavarian Nordic GmbH, Revolution Medicines, Inc., Bryn Mawr Hospital Foundation, PureSight Advisory LLC, The Haverford School and The Wistar Institute. Ms. Anderson was previously employed as a Vice President-Infectious Disease & Vaccines by Janssen Pharmaceuticals, Inc. and a VP& General Manager-Wyeth Lederle Vaccines by Johnson & Johnson. She received her undergraduate degree from Rutgers State University of New Jersey and an MBA from Loyola University New Orleans.
Camilla V. Simpson Camilla V. Simpson is on the board of Spruce Biosciences, Inc. and Senior VP & Head-Product Portfolio Development at BioMarin Pharmaceutical, Inc. Ms. Simpson received a graduate degree from Birkbeck University of London, an undergraduate degree from National University of Ireland and an undergraduate degree from Kingston University.
Dave Jacoby Dave Jacoby is Executive Group Medical Director at BioMarin Pharmaceutical, Inc.
Steve Maricich Steve Maricich is Medical Director-Clinical Sciences at BioMarin Pharmaceutical, Inc.
Brad Glasscock Brad Glasscock is Group VP & Head-Global Regulatory Affairs at BioMarin Pharmaceutical, Inc.
Brinda Balakrishnan Brinda Balakrishnan founded Vision Medicines, Inc. Dr. Balakrishnan is Vice President-Corporate & Business Development at BioMarin Pharmaceutical, Inc. In her past career Dr. Balakrishnan occupied the position of VP-Corporate Strategy & Product Development at Vision Medicines, Inc. She received an undergraduate degree and a doctorate from Massachusetts Institute of Technology and a doctorate from Harvard Medical School.
Benjamin Kim Benjamin Kim is Senior Medical Director-Clinical Science at BioMarin Pharmaceutical, Inc.
SAba Sile SAba Sile is Medical Director of BioMarin Pharmaceutical, Inc.
Amy Wireman Presently, Amy Wireman is Group Vice President-Human Resources at BioMarin Pharmaceutical, Inc. She received an undergraduate degree from New York University.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐